Posted by Michael Wonder on 29 May 2024
Trastuzumab deruxtecan for the treatment of patients with advanced HER2 mutation positive non-small-cell lung cancer after platinum-based chemotherapy
29 May 2024 - NICE is unable to make a recommendation on the use of trastuzumab deruxtecan (Enhertu) for the treatment of adults with advanced HER2 mutation positive non-small-cell lung cancer after platinum-based chemotherapy because Daiichi Sankyo did not provide an evidence submission.
NICE will review this decision if Daiichi Sankyo decides to make a submission.
